Skip to main content
Premium Trial:

Request an Annual Quote

ABI to Launch Assays-on-Demand Line Tomorrow

NEW YORK, July 9 - Applied Biosystems will launch its long-awaited Assays-on-Demand tools tomorrow, a person close to the company told GenomeWeb today.


The Assays-on-Demand suite comprises a SNP-genotyping tool and a gene-expression product. Its cost to customers is closely guarded.


For its SNP-genotyping tool, ABI selects SNPs from data provided by Celera Genomics and public sources. The assays, based on next-generation TaqMan probe technology, are validated against 90 individual DNA samples from two populations, ABI said on its web site.


The gene-expression products, meanwhile, are pre-formulated gene-expression assays used to detect and quantify human mRNA transcripts. The assays, which were built to work on ABI's PRISM sequence-detection system, are designed to amplify target cDNA without amplifying genomic DNA, according to ABI.


Gene-expression quantification is done in a two-step RT-PCR process in which the PCR step is coupled with the fluorogenic 5' nuclease chemistry.


An ABI spokeswoman did not return multiple telephone calls seeking comment. An ABI official, citing uniform disclosure rules, would not confirm whether both tools would be available on Wednesday.


Click here to learn more about the Assay-on-Demand tools.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.